![]() | |
Clinical data | |
---|---|
Other names | 16α-Ethylthiodydrogesterone; 16α-Ethylthio-6-dehydroretroprogesterone; 16α-Ethylthio-9β,10α-pregna-4,6-diene-3,20-dione |
Routes of administration | Oral |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
Chemical and physical data | |
Formula | C23H32O2S |
Molar mass | 372.57 g·mol−1 |
3D model (JSmol) | |
| |
|
Ro 6-3129, also known as 16α-ethylthio-6-dehydroretroprogesterone or as 16α-ethylthio-9β,10α-pregna-4,6-diene-3,20-dione, as well as 16α-ethylthiodydrogesterone, is a progestogen of the retroprogesterone group which was developed by Roche but was never marketed.[1][2][3] It shows greater potency than dydrogesterone in bioassays.[4]
References
[edit]- ^ Harper MJ (1977). "Contraception — retrospect and prospect". In Jucker E (ed.). Progress in Drug Research. Vol. 21. pp. 293–407 [321]. doi:10.1007/978-3-0348-7098-6_4. ISBN 978-3-0348-7098-6. PMID 339271.
- ^ Larsson-Cohn U, Johansson ED, Wide L, Gemzell C (September 1970). "Effects of daily administration of a retrosteroid on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens". The Journal of Obstetrics and Gynaecology of the British Commonwealth. 77 (9): 840–846. doi:10.1111/j.1471-0528.1970.tb04411.x. PMID 5458777. S2CID 6176278.
- ^ Dixon R, Hudson S, Darragh A (1973). "Pharmacokinetics of the retro-steroid progestogen, 16α-ethylthio-9β,10α-pregna-4, 6-diene-3, 20-dione (Ro 6-3129), in man and the sheep". Contraception. 8 (1): 53–65. doi:10.1016/0010-7824(73)90159-5. ISSN 0010-7824.
- ^ The Journal of Obstetrics and Gynaecology of the British Commonwealth. Royal College of Obstetricians and Gynaecologists. 1970.